混合测试在合并获得的血友病A和凝血因子缺乏症的情况下:一个病例报告
Osamu Imataki1, Keigo Takahata1, Yuko Mukai1
1Laboratory Medicine, Kawasaki Medical School, Okayama, JPN.
Cureus
|December 22, 2025
概括
获得的血友病A和B是一种罕见的出血障碍,是由针对凝血因子的抑制剂引起的. 一种新的百分比校正混合测试方法准确地诊断出一种复杂的获得性血友病A病例,同时存在肝脏相关因子缺乏症.
科学领域:
- 血液学 血液学 血液学
- 自身免疫性疾病 自身免疫性疾病
- 临床诊断 临床诊断 临床诊断
背景情况:
- 获得的血友病A和B是罕见的自身免疫性疾病,其特点分别是对凝血因子VIII和IX的抑制剂.
- 这些疾病表现为过度出血,并经常通过混合测试模式与凝血因子缺乏 (例如肝病) 区分开来.
- 由于凝血研究中的重叠特征,区分抑制剂和缺乏模式可能具有挑战性.
研究的目的:
- 评估百分比校正方法在混合试验中的实用性,以区分获得的血友病与凝血因子缺乏.
- 报告一个复杂的同时获得的血友病A和肝脏相关的凝血因子缺乏症的复杂病例.
- 突出诊断挑战和高级混合试验分析在双病理凝血病的有效性.
主要方法:
- 一名患有严重出血的70岁男性患者接受了全面的凝血研究,包括延长激活部分血栓形成时间 (aPTT).
- 在新鲜冷血 (FFP) 给药前和后进行了1:1%的校正混合试验.
- 进行了混合测试模式 (缺乏与抑制剂) 的分析和特定抑制剂的识别.
主要成果:
- 最初的混合测试表明缺陷模式,这与FPF没有改善.
- 在FFP后,混合测试显示了双相模式 (缺乏然后抑制剂),表明叠加的抑制剂.
- 确定了对凝血因子VIII的抑制剂,证实了获得的血友病A作为主要诊断.
结论:
- 1:1%校正混合试验方法是区分复杂凝血病的抑制剂和缺乏模式的可靠工具.
- 获得的血友病A是该患者严重出血的主要原因,尽管存在潜在的凝血因子缺乏.
- 混合试验和血补充剂的联合使用有助于澄清出血乱的双重致病机制.
更多相关视频
相关概念视频
01:24Disorders of Hemostasis
1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
02:45Blood Transfusion and Agglutination
13.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
13.9K
01:09Coagulation
9.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.5K
01:06Coagulation
1.2K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.2K